title: [Targeted therapies in digestive oncology].
abstract: Targeted therapies are relatively new molecules available for the oncologist. These drugs target a specific step of the cellular development and interfere with the intracellular signalization pathways. Amongst all others, EGF- and VEGF-pathways are currently targeted by these selective therapies. Modulating EGF and VEGF significantly improves overall survival and progression-free survival for many advanced or metastatic tumors as colorectal cancer, gastric cancer, gastrointestinal stromal tumors or hepatocellular carcinoma. Targeted therapies have a specific action site, a simple administration mode and are relatively well tolerated. In the future these molecules will probably be used "à la carte" for tumors that appear to be refractory to other drugs.
authors: Service d'oncologie, Département de chirurgie HUG, 1211 Genève 14. Marie-Laure.Amram@hcuge.ch
authors: M-L
authors: ML
authors: Amram
authors: D A
authors: DA
authors: Benamran
authors: A D
authors: AD
authors: Roth
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004067:Digestive System Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D058990:Molecular Targeted Therapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D013274:Stomach Neoplasms / Q000188:drug therapy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor